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ﬁndings suggest that GVHD, even in sub-clinical stages, may
impair diversiﬁcation of the immune repertoire. We evalu-
ated post-HCT B cell immunoglobulin heavy chain (IGH) gene
diversity in 42 patients with chronic lymphocytic leukemia
who received unmanipulated mobilized peripheral blood
grafts following total lymphoid irradiation and anti-thymo-
cyte globulin (TLI/ATG). Twenty-one patients also received 4
weekly doses of Rituximab beginning 2 months post-HCT.
Post-HCT peripheral blood samples were prospectively
archived at pre-scheduled intervals. The IGH repertoire was
quantiﬁed in over 400 samples using the LymphoSIGHT(TM)
method, which employs consensus IGH V and J segment
primers to universally amplify rearranged IGH genes, fol-
lowed by massively parallel high-throughput sequencing
(IGH-HTS) and bioinformatic analysis. Donor graft material
was analyzed in the same manner. A median 1.8x10e6
(2.6x10e4 e 2.7x10e6) leukocyte genomes per sample with
a median 6.4x10e5 (12 e 7.6x10e5) IGH molecules were
analyzed. Compared to healthy donors, patients receiving
only TLI/ATG exhibited signiﬁcantly decreased diversity at
days +30 and +90 (p<0.001) (Figure 1A), whereas IGH
diversity remained signiﬁcantly decreased at days +30, +90,
+180, +270 (each P < .001) and +365 (p<0.05) in those who
received post-HCT Rituximab (Figure 1B). Clonotype analysis
conﬁrmed signiﬁcant (p¼0.009) but incomplete depletion of
adoptively transferred IGH clones in those receiving post-
HCT Rituximab (Figure 1C). The incidences of relapse (38 vs.
52%) and new-onset GVHD (28 vs. 33%) were similar in the
two groups. Amongst patients at risk for new onset GVHD
(after censoring for relapse and Rituximab treatment), IGH
diversity was signiﬁcantly decreased at day +30 (54 +/- 13 vs.
18818 +/- 11576 unique IGH clones; P ¼ .03) and day +90
(2693 +/- 2657 vs. 40316 +/- 16480 unique IGH clones; P ¼
.02) in those who subsequently developed GVHD in
comparison to those who did not (Figure 1D). IGH-HTS
analysis of the adoptively transferred and reconstituting B
cell repertoires after allo-HCT may provide a method for
predicting new onset GVHD and for identifying pathogeni-
cally involved adoptively transferred B cell clones.
Figure 1. Box and whisker plots demonstrating post-HCT IGH clonotypc
diversity in the peripheral blood of patients allografted after conditioning with
TLI/ATG (A) or TLI/ATG + post-HCT Rituximab (B). Mean (+s.e.m.) number of
adoptively transferred IGH elonotypes in patients conditioned with TLI/ATO
(solid line) or TLJ/ATG Riluximab (dotted line) (C). IGH clonotype diversity at
days +30 and +90 post-HCT in patients who did (GVHD+; red) or did not (No
GVHD; black) subsequently develop GVHD) after censoring for relapse,
Riluximab treatment, and prior GHVD (D). Numbers on graph indicate
evaluable patients at each time point.72
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Umbilical cord blood transplantation (UCBT) is increas-
ingly used as an alternative source for allogeneic hemato-
poietic stem cell transplantation. A signiﬁcant component of
immune reconstitution after UCBT involves thymic regen-
eration, which can be measured by T-cell receptor rear-
rangement excision circles (TRECs). TREC levels are a strong
predictive factor for overall survival in adult recipients of
UCBT. Injury of the thymic microenvironment, particularly
of thymic epithelial cells (TEC), during HSCT compromises
thymopoiesis. Human UCB is enriched in endothelial
precursors that can sustain thymopoiesis in immunodeﬁ-
cient mice transplanted with human thymic grafts, where
they engraft and promote neovascularization and wound
healing. We examined markers of angiogenesis and neo-
vascularization ANG1 and VEGF associated with TEC func-
tion, thymic regeneration and T cell reconstitution in
patients after double reduced intensity UCBT. 27 evaluable
patients with a median age of 50 years with hematopoietic
malignancies were treated with (Flu/Mel/rATG) condi-
tioning followed by double UCBT; GvHD prophylaxis was
tacrolimus and sirolimus. At various time points Which ones
after UCBT, serum levels of IL-7 and SCF that are produced
by TEC displayed a strong correlation (p<0.005) with ANG1
and VEGF indicating that functional recovery of TEC is
associated with angiogenesis and neovascularization. In
contrast, serum levels of IL-7 and SCF displayed a strong
inverse correlation (p<0.001) with TREC, CD4+, CD8+ and
Treg numbers suggesting that uptake of these cytokines by
cognate IL-7R and Kit receptor on immature T cell progen-
itors resulted in their differentiation and expansion. IL-7
and SCF also displayed a strong inverse correlation
(p<0.001) with the ability of T cells to differentiate into
pathogen-speciﬁc effectors as determined by CMV-speciﬁc
IFN-g ELISpot. Conversely, VEGF and ANG1 levels positively
correlated (p<0.001) with CD4+, CD4+CD25+ and
CD4+CD45RA+ numbers. Our results are consistent with
a model in which ANG1 and VEGF support TEC recovery
leading to production of SCF and IL-7 by TEC and uptake of
these cytokines by T cell progenitors resulting in their
differentiation and expansion. These sequential steps in the
process of thymic regeneration might represent novel
therapeutic targets for improvement of immune reconsti-
tution after UCBT.
